Durata files NDA for infectious disease drug; KaloBios eyes $27.8M;

@FierceBiotech: Popular yesterday: In another stinging setback, Eli Lilly's ramucirumab fails PhIII breast cancer study. Article | Follow @FierceBiotech

@JohnCFierce: ICYMI: Nektar Therapeutics shares crash on PhII pain drug trial flop. Story | Follow @JohnCFierce

@DamianFierce: After a so-so IPO, Regado is axing 15% of its employees, mostly in R&D. Article | Follow @DamianFierce

> Durata Therapeutics ($DRTX) has submitted an NDA for dalbavancin, designed to treat skin structure infections caused by microorganisms like MRSA. Story

> Novo Nordisk ($NVO) is touting positive Phase III data for IDegLira, an investigational combination of Tresiba and Victoza for Type 2 diabetics. More

> Nonprofit CureDuchenne has launched a venture arm, making its first investment in Lexicon Pharmaceuticals ($LXRX), whose LX2931 may have applications in muscular dystrophy. Item

> GlaxoSmithKline ($GSK) has teamed up with Barclays to launch a new fund that will increase access to healthcare in Zambia. News

> KaloBios ($KBIO) is looking to raise $27.8 million by selling 7.5 million shares at $4 each. Article

> A little-used class of FDA-approved antidepressants could be repurposed to treat small-cell lung cancer, researchers say. Story

Medical Device News

@FierceMedDev: axes jobs after FDA warns over pump. News | Follow @FierceMedDev

@MarkHFierce: KKR sealed the deal to buy Panasonic's healthcare business for $1.67B. Higher than expected. Press release | Follow @MarkHFierce

@MichaelGFierce: Laser-sensitive surface enables IV-drug identification for safer delivery. ICYMI from FierceDrugDelivery | Follow @MichaelGFierce

> Medtronic wins FDA nod to roll out auto-stop insulin device. Report

> Singulex grabs $55M in debt, equity for global in vitro diagnostics push. Article

Pharma News

@FiercePharma: Top story yesterday online: If reps can't get in doctors' front doors, try alternate routes. Item | Follow @FiercePharma

@EricPFierce: Judge smokes jury's $1.7 million verdict against Takeda for not properly warning on Actos dangers. Article | Follow @EricPFierce

> Japan authorities digging deeper into Novartis' use of flawed Diovan study. More

> U.K.'s nod to J&J's Caelyx comes even as shortages expected. Article

> U.K. to extend cancer drug fund for treatments NICE rejects. Story

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.